BION.S
Latest Trade
67.05CHFChange
-0.15(-0.22%)Volume
111,911Today's Range
-
67.4552 Week Range
-
73.65As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay
Previous Close | 67.20 |
|---|---|
Open | 67.45 |
Volume | 111,911 |
3M AVG Volume | 2.00 |
Today's High | 67.45 |
Today's Low | 65.70 |
52 Week High | 73.65 |
52 Week Low | 55.05 |
Shares Out (MIL) | 55.40 |
Market Cap (MIL) | 3,722.88 |
Forward P/E | 12.44 |
Dividend (Yield %) | -- |
BB Biotech Expands Board Of Directors
BB Biotech Q3 Net Loss At CHF 382 Mln
BB Biotech Sees Portfolio Cos To Report Q4 Pipeline Progress
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Industry
Misc. Financial Services
Executive Leadership
Erich Hunziker
Chairman of the Board
Clive A. Meanwell
Vice Chairman of the Board of Directors
Michael Hutter
Chief Financial Officer, Chief Compliance Officer
Rudy Le Blanc
Board Member and Managing Director of the BB Biotech Branch Office in Curacao
Tanja Chicherio
Marketing & Communication Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 636.72 |
Price To Book (MRQ) | 1.29 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 11.77 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -14.67 |
Return on Equity (TTM) | -13.27 |
* DGAP-ADHOC: BB BIOTECH AG: EXPANSION OF THE BOARD OF DIRECTORS
* EXPECTS PORTFOLIO COMPANIES TO REPORT SUBSTANTIAL PIPELINE PROGRESS DURING Q4 Source text for Eikon: Further company coverage: (Gdansk Newsroom)
* NET PROFIT FOR PERIOD ENDED SEPTEMBER 30, 2019 AMOUNTED TO CHF 172 MN (PROFIT OF CHF 172 MN IN SAME PERIOD 2018)
* CONSOLIDATION LEAVES A MARK ON RESULTS IN THE SECOND QUARTER
* Q1 PROFIT OF CHF 890 MN (PROFIT OF CHF 28 MN IN CORRESPONDING PERIOD OF PREVIOUS YEAR) Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* SAID ON THURSDAY CONCLUDES ITS SHARE BUYBACK PROGRAM AND LAUNCHES A NEW BUYBACK PROGRAM
* FY NET LOSS OF CHF 471 MN COMPARED TO A NET GAIN OF CHF 688 MN FOR FULL YEAR OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* BB BIOTECH INVESTS GAINS OF M&A TRANSACTIONS IN NEW TECHNOLOGIES - DIVIDEND OF CHF 3.05 PROPOSED
* SAYS CLOSED ITS FISCAL YEAR 2018 WITH A LOSS OF APPROXIMATELY CHF 471 MILLION, BASED ON ITS PRELIMINARY UNAUDITED CONSOLIDATED RESULTS Source text for Eikon: [ID:urn:newsml:newsroom:20190118:nNRA7s1b3z:0] Further company coverage: (Reporting By Zurich newsroom)
* WILL PROPOSE DR. THOMAS VON PLANTA FOR ELECTION TO ITS BOARD OF DIRECTORS.
* DGAP-NEWS: BB BIOTECH AG: INVESTORS SHOWED RENEWED INTEREST IN BIOTECH STOCKS DURING THE THIRD QUARTER
* FOR NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2018 A PROFIT OF CHF 172 MILLION VERSUS CHF 843 MILLION YEAR AGO
* Q2 NET LOSS OF CHF 98 MN. VERSUS NET PROFIT OF CHF 103 MN REPORTED FOR Q2 OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* H1 LOSS OF AROUND CHF 70 MLN (CHF 478.4 MLN PROFIT IN CORRESPONDING PERIOD OF PREVIOUS YEAR) Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* DGAP-ADHOC: BB BIOTECH SHARE GAINS VALUE IN FIRST QUARTER 2018 - SEVERAL LARGE-CAP BIOTECH COMPANIES TRADING AT WELL BELOW FUNDAMENTAL VALUE
* FY NET GAIN OF CHF 688 MN COMPARED TO A NET LOSS OF CHF 802 MN IN PREVIOUS PERIOD
* SHOWS A DOUBLE-DIGIT TOTAL RETURN FOR 2017 - MID CAPS OVERDELIVER ON INNOVATION AND ARE BECOMING A KEY UPSIDE TRIGGER
* BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING Source text: (http://bit.ly/2CZEeZD) Further company coverage:
* PRODUCT APPROVALS AND SOLID COMPANY RESULTS LEAD THE BIOTECH SECTOR HIGHER
* BB Biotech AG reports 5.1 percent passive stake in Intra-Cellular Therapies Inc as of August 18, 2017 - SEC filing Source text: (http://bit.ly/2xcLrz4) Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.